- Durata Therapeutics (DRTX) says the FDA has approved its Dalvance antibiotic for the treatment of patients with acute bacterial skin and skin structure infections.
- Dalvance is the first drug with the qualified infectious disease product designation to receive FDA approval.
- A March FDA advisory panel approval also had given a favorable review to a rival product from Cubist Pharmaceuticals (CBST); the FDA is set to rule on the CBST drug shortly.
- DRTX shares halted.
From other sites
at CNBC.com (Oct 6, 2014)
at CNBC.com (Aug 4, 2014)
at CNBC.com (Mar 31, 2014)
at CNBC.com (Jul 20, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs